TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23292545
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (CM)
Study: 19019053
Drug: Wound perfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound perfusion with 8 mL of 0.25% bupivacaine every 5 hours
Study: 19019053
Drug: Intravenous pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pethidine 0.2 mg/kg on demand
Study: 15117890
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist plus raloxifene (leuprolide acetate depot at 3.75 mg/28 days and raloxifene hydrochloride at 60 mg/day for 18 cycles)
Study: 12200524
Drug: eformoterol Turbohaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: eformoterol Turbohaler 9 microg (delivered dose)
Study: 12200524
Drug: budesonide Turbohaler
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: budesonide Turbohaler 400 microg twice daily
Study: 9618752
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) up to 0.25 U/kg per week in daily doses
Study: 1837965
Drug: 0.150 mg
Normalized name: LEVOTHYROXINE SODIUM 0.150 mg ORAL TABLET [LEVOTHYROXINE SODIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.150 mg Desogestrel and 0.030 mg Ethinylestradiol
Study: 1837965
Drug: 0.075 mg
Normalized name: mestranol 0.075 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 mg Gestoden and 0.030 mg Ethinylestradiol
Study: 1837965
Drug: 0.250 mg
Normalized name: DIGOXIN 0.250 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.250 mg Norgestimat and 0.035 mg Ethinylestradiol
Study: 25211767
Drug: Combination hearing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination hearing aid with noise feature activated (experimental group, n=15)
Study: 24849708
Drug: Nintedanib 150
Normalized name: nintedanib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 150 mg (arm A)
Study: 24849708
Drug: Nintedanib 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 250 mg (arm B)
Study: 19687168
Drug: Surgery and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery and l-T(4) abstinence
Study: 17312403
Drug: Intranasal (IN)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (IN) measles vaccine
Study: 17312403
Drug: Subcutaneous (SQ)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SQ) measles vaccine
Study: 17312403
Drug: Both IN
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both IN and SQ vaccines
Study: 8082354
Drug: Spacer device
Normalized name: E-Z Spacer Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spacer device with inhaled beta-agonist at discharge
Study: 8082354
Drug: Inhaled or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled or oral beta-agonists without a spacer device
Study: 2683547
Drug: No H2
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No H2 receptor antagonist (Control)
Study: 747177
Drug: Naltrexone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 25 mg first-day dose
Study: 747177
Drug: Naltrexone 100
Normalized name: naltrexone 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 100 mg first-day dose
Study: 747177
Drug: Naltrexone 150
Normalized name: METHYLNALTREXONE 150MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 150 mg first-day dose
Study: 747177
Drug: Naltrexone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone maintenance regimen in Group A (5 times weekly)
Study: 747177
Drug: Naltrexone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone maintenance regimen in Group B (3 times weekly)
Study: 747177
Drug: Naltrexone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone maintenance regimen in Group C (2 times weekly)
Study: 31987769
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD) group received 4 mg of folic acid daily from the first 3 months of pregnancy until the entire pregnancy.
Study: 31987769
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (LD) group received 0.4 mg of folic acid daily from the first 3 months of pregnancy until the entire pregnancy.
Study: 31987769
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD) group with compliance >50%.
Study: 28237842
Drug: Treatment (mobile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (mobile application)
Study: 21248209
Drug: Conventional outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional outpatient physical therapy
Study: 9340922
Drug: Supraphysiologic magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraphysiologic magnesium administration
Study: 3319722
Drug: Oxiconazole cream,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiconazole cream, applied once daily
Study: 27575834
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with 50 J dose
Study: 27575834
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with 10 J dose
Study: 27575834
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with 10 J and 50 J doses
Study: 27575834
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with 30 J dose
Study: 24689258
Drug: Cognitive load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive load (high load conditions with a concurrent working memory task using auditory stimuli)
Study: 8792045
Drug: Testosterone cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cypionate 300 mg/week
Study: 8792045
Drug: Testosterone cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cypionate 600 mg/week
Study: 29079411
Drug: Capecitabine (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1250 mg/m2 orally twice daily, days 1-14, every 21 days)
Study: 29079411
Drug: S-1 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (40 mg/m2 orally twice daily, days 1-28, every 42 days)
Study: 22341040
Drug: Comprehensive rehabilitation
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive rehabilitation programme combined with acetaminophen 1g three times a day (group B)
Study: 20356555
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (LH)
Study: 20356555
Drug: Low-dose unfractionated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose unfractionated heparin (LUFH)
Study: 20356555
Drug: Low-dose low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose low molecular weight heparin (LLMWH)
Study: 20356555
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight unfractionated heparin (LLMWUFH)
Study: 20356555
Drug: High-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose heparin (HH)
Study: 20356555
Drug: High-dose low
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose low molecular weight heparin (HLMWH)
Study: 10633209
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of iron per day (nutritional supplement made from bovine blood)
Study: 7797897
Drug: Bivalent live
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent live attenuated influenza A virus vaccine
Study: 21658476
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy for Insomnia (CBT-I)
Study: 19705924
Drug: Bilastine 5
Normalized name: bilastine
DrugBank: Bilastine (DB11591)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Bilastine 5 mg
Study: 16500251
Drug: Johns Hopkins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Johns Hopkins Antibiotic Guide (JHABX) on the RIM Blackberry PDA
Study: 11575443
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml water containing 10 mg Cu/L (as copper sulfate)
Study: 11575443
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml distilled water
Study: 8118750
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - 2 mg 17 beta-estradiol plus 1 mg norethisterone daily for 1 year
Study: 8118750
Drug: Nandrolone Decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone Decanoate (ND) - 50 mg i.m. every 3 weeks for 1 year
Study: 3415895
Drug: MHS(B) -
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHS(B) - morphine hydrogel suppository with high initial release rate
Study: 3415895
Drug: MHS(S) -
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHS(S) - morphine hydrogel suppository with constant release rate
Study: 29231336
Drug: Conventional triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional triple drugs (omeprazole, amoxicillin and clarithromycin) for Hp positive patients, and omeprazole for Hp negative patients
Study: 25872149
Drug: Single-dose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose treatment of AM-101
Study: 25872149
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of AM-101 over 2 weeks
Study: 25872149
Drug: Three injections
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three injections of AM-101 over 3 consecutive days
Study: 12956495
Drug: IMZ two-stage
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMZ two-stage implants
Study: 12956495
Drug: ITI one-stage
Normalized name: Arthur Itis
DrugBank: Trolamine salicylate (DB11079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ITI one-stage implants
Study: 8368558
Drug: Total Intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Intravenous Anesthesia (6.0 mg.kg‐1 x h‐1 propofol)
Study: 2947345
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (Provera) 20 mg orally thrice daily for one month
Study: 30257641
Drug: As concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: As concentration >=0.02 mg/kg
Study: 30257641
Drug: Ni concentration
Normalized name: Toto ni vavalagi oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ni concentration >=0.1232 mg/kg
Study: 30257641
Drug: Se concentration
Normalized name: Low glucose concentration peritoneal dialysis solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Se concentration >=0.02 mg/kg
Study: 30257641
Drug: Fe concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe concentration >=6.9153 mmol/L
Study: 30257641
Drug: Ni concentration
Normalized name: Toto ni vavalagi oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ni concentration >=0.0965 mg/kg
Study: 28870472
Drug: High β‐glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High β‐glucan barley (4.4 g/d)
Study: 28870472
Drug: High β‐glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High β‐glucan barley (4.4 g/d) in subgroup with VFA ≥100 cm2
Study: 20350051
Drug: Glycyrrhizin salt
Normalized name: glycyrrhizinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhizin salt tablet 150 mg twice daily for 14 consecutive days
Study: 18486720
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and medication therapy to lower urine supersaturation
Study: 10509788
Drug: Cyclophosphamide (CYCLO)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CYCLO) at a dose of 1200 mg/m2
Study: 10509788
Drug: Ifosfamide (IFOS)
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide (IFOS) at a dose of 5 g/m2
Study: 1781536
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml of clear fluid 1.5‐2 hours before anaesthesia
Study: 6792382
Drug: Protein-containing solution
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-containing solution with hypertonic glucose
Study: 6792382
Drug: Protein-free solution
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-free solution
Study: 30831601
Drug: Current use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current use of soy supplements
Study: 27256356
Drug: nasally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasally administered oxytocin
Study: 19501409
Drug: Topical gatifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gatifloxacin for 3 days before injection
Study: 19501409
Drug: Topical gatifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gatifloxacin in combination with PVI
Study: 10857960
Drug: KJM fiber-enriched
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KJM fiber-enriched test biscuits (0.5 g of glucomannan per 100 kcal of dietary intake or 8-13 g/day)
Study: 30548390
Drug: Metformin (n=27)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (n=27)
Study: 30548390
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Metformin and Placebo)
Study: 29795172
Drug: High-Intensity Interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Interval Training (HIIT) - exercised twice a week at 85–95% of HRmax
Study: 29795172
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - treatment as usual
Study: 27716200
Drug: Internet cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet cognitive-behavioural therapy (CBT) with seven experimental factors (activity scheduling, functional analysis, thought challenging, relaxation, concreteness training, absorption, self-compassion training)
Study: 27716200
Drug: Internet cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet cognitive-behavioural therapy (CBT) with seven experimental factors
Study: 22140146
Drug: Cigarettes with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes with 10.1 μg ammonia per cigarette
Study: 22140146
Drug: Cigarettes with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes with 18.9 μg ammonia per cigarette
Study: 18515949
Drug: Drug-regimens for
Normalized name: benzphetamine hydrochloride Oral Tablet [Regimex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-regimens for fracture prevention
Study: 18515949
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of different drug-regimens
Study: 16164375
Drug: Non-medical and
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-medical and non-surgical therapies for palliative care
Study: 29793605
Drug: ABP-700 (infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABP-700 (infusion doses varying, continuous infusion for 30 minutes)
Study: 29793605
Drug: Propofol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (60 μg kg-1 min-1)
Study: 27758992
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of positive Xpert MTB/RIF, positive tuberculin skin test, heterogeneous echotexture of lymph nodes, or endosonographic coagulation necrosis sign
Study: 23242731
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% caudally (0.5 ml/kg)
Study: 23242731
Drug: Levobupivacaine 0.25%
Normalized name: levobupivacaine 0.25% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.25% caudally (0.5 ml/kg)
Study: 8903817
Drug: Sulfate-free polyethylene
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfate-free polyethylene glycol electrolyte lavage solution (SF-PEG-ELS)
Study: 8140562
Drug: Selegiline (S)
DrugBank: Selegiline (DB01037)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selegiline (S) 10 mg/day
Study: 27602665
Drug: Adalimumab (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (loading dose of 80 mg followed by 40 mg every 2 weeks)
Study: 17274828
Drug: CORE (1028
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORE (1028 mg daily)
Study: 16227771
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy initiated in-hospital
Study: 7888977
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch treatment (16 hours per day for 18 weeks)
Study: 7888977
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch treatment
Study: 7888977
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch treatment with gradual reduction
Study: 7888977
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch treatment with dose increase after week 1
Study: 2198812
Drug: 0.5% betaxolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% betaxolol ophthalmic solution
Study: 857138
Drug: 300 mg/die
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/die Allopurinol
Study: 857138
Drug: 100 mg/die
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/die Benzbromarone
Study: 857138
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Allopurinol with 20 mg Benzbromarone
Study: 30924163
Drug: EA-230 (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA-230 (90 mg/kg/hour for 2 hours)
Study: 30924163
Drug: EA-230 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA-230 (1, 3, 10, or 30 mg/kg single dosage)
Study: 30924163
Drug: EA-230 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA-230 (10, 20, or 30 mg/kg, thrice daily for 3 days)
Study: 30924163
Drug: EA-230 (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA-230 (15, 30, or 90 mg/kg/hour for 2 hours)
Study: 29354954
Drug: No.1 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No.1 treatment group (ginger-prepared paste)
Study: 29354954
Drug: No.2 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No.2 treatment group (honey-prepared paste)
Study: 29354954
Drug: No.3 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No.3 treatment group (honey-prepared paste, 6h application)
Study: 20544178
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of calcium and 400 IU of vitamin D3
Study: 15380859
Drug: Olanzapine, 5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine, 5-20 mg/day for 8 months
Study: 2491707
Drug: Cefuroxime-axetil (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime-axetil (250 mg twice daily after meal)
Study: 2491707
Drug: Cefadroxil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil (1 g twice daily during meal)
Study: 31745044
Drug: Phonophoresis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonophoresis with aceclofenac gel
Study: 23636029
Drug: Reflexology therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reflexology therapy (AEDs + reflexology therapy)
Study: 12101597
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs (Control)
Study: 20029710
Drug: Greater AD
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater AD treatment optimism
Study: 16484699
Drug: Thalidomide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (100 mg/d orally, escalated to 400 mg/d)
Study: 16484699
Drug: Medroxyprogesterone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxyprogesterone (300 mg orally daily)
Study: 7034641
Drug: Ceforanide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceforanide (0.5 g every 12 h)
Study: 7034641
Drug: Cefazolin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1.0 g every 8 h)
Study: 29045315
Drug: ATP supplementation
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATP supplementation (400 mg)
Study: 27696395
Drug: Nab-paclitaxel at
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel at a dose of 175 mg/m2 plus nedaplatin at a dose of 80 mg/m2 administered intravenously every 3 weeks
Study: 8534461
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ketorolac IV
Study: 8534461
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ketorolac IM
Study: 2725118
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine system (TNS) 10, 20, and 40 mg/24 h
Study: 2725118
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine system (TNS) delivering 14 mg nicotine/24 h